Patient profiles are representative
and not actual DUPIXENT patients.
Felix’s clinical profile and challenges
- Dyspnea can get in the way of his daily activities
- History of hypertension, depression, and sleep apnea
- Experienced a severe COPD exacerbation in the previous 12 months
- Compliant with triple inhaled therapy (LAMA + LABA + ICS)
- Elevated blood EOS level, a marker of type 2 inflammation
Explore DUPIXENT data
for a patient like Felix
Up to 34% Reduction in Exacerbations1-3
(PRIMARY ENDPOINT)BOREAS Trial
30% reduction in the annualized rate of moderate or severe exacerbationsa for DUPIXENT + triple therapy (0.78 exacerbations per year [n=468] vs 1.10 for placebo + triple therapy [n=471]; P<0.001)b
NOTUS Trial34% reduction in the annualized rate of moderate or severe exacerbationsa for DUPIXENT + triple therapy (0.86 exacerbations per year [n=470] vs 1.30 for placebo + triple therapy [n=465]; P<0.001)c
Patients showed improvement in lung function through week 521,d
Change in post-bronchodilator FEV1 from baseline at Week 12 and Week 52 (ITT population; secondary endpoint)1
BOREAS Trial138 mL numerical improvement for DUPIXENT + triple therapy (n=468) vs 58 mL for placebo + triple therapy (n=471) at Week 521
NOTUS Trial127 mL numerical improvement for DUPIXENT + triple therapy (n=362) vs 59 mL for placebo + triple therapy (n=359) at Week 52 (LSM change from baseline, ITT population)1,5
Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.
Significant improvements of similar magnitude were observed in change from baseline in pre-bronchodilator FEV1 at Weeks 12 and 52 in subjects treated with DUPIXENT compared to placebo across the BOREAS and NOTUS trials.
Based on a post hoc pooled analysis of BOREAS and NOTUS,
COPD EXACERBATIONS LEADING TO HOSPITAL VISITSe REDUCED BY 38%9
In patients on DUPIXENT + triple therapy vs placebo + triple therapy, 0.16 for placebo (0.12-0.22) vs 0.10 for DUPIXENT (0.07-0.14)
(N=1874; OR: 0.621; 95% Cl; 0.427 .901) adjusted annualized rate of exacerbations leading to hospital visits9,f
Results are descriptive. Definitive conclusions cannot be made.
aModerate exacerbations were defined as exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were defined as exacerbations that led to hospitalization or an emergency medical care visit or that resulted in death.1-3
bRate ratio vs placebo: 0.71 (95% CI: 0.58-0.86).1
cRate ratio vs placebo: 0.66 (95% CI: 0.54, 0.82).1
dIn the NOTUS trial, patients administered DUPIXENT + triple therapy saw nominal improvement in post-bronchodilator FEV1 of 134 mL at Week 12 and 127 mL at Week 52 (n=362), compared with 67 mL at Week 12 (n=465) and 59 mL at Week 52 (n=359) in patients receiving placebo + triple therapy (LSM change from baseline, ITT population).1,5
eHospital visits is hospitalization or emergency department visits of any duration.9
fBased on a post hoc analysis of BOREAS and NOTUS; phase 3, randomized, double-blind, placebo-controlled trials. Adjusted annualized rate of severe exacerbations and/or ED visits of patients ages 40 to 85 years with COPD, moderate-to-severe airflow limitation, and type 2 inflammation (screening blood eosinophils ≥300 cells/µL) on LABA/LAMA/ICS. Patients received add-on dupilumab 300 mg or matching placebo Q2W for up to 52 weeks. Severe exacerbations and/or ED visits defined as exacerbations requiring hospitalization or an emergency department visit of any duration.9